Overview

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating patients who have metastatic melanoma. Thalidomide combined with SU5416 may stop the growth of metastatic melanoma by stopping blood flow to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Semaxinib
Thalidomide